165 An Analysis of the Use of Andexanet Alfa at the University of Utah Hospital
Saved in:
| Main Authors: | James R. Gustat, Aubrey E. Jones, Daniel M. Witt |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037925001384 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Andexanet alfa: trials just leave us with more questions
by: Richard J. Buka
Published: (2025-01-01) -
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality
by: Huiqiao Fan, et al.
Published: (2025-01-01) -
Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding
by: Alexander T. Cohen, et al.
Published: (2022-04-01) -
Andexanet alfa for oral fxa inhibitor-associated major acute intracerebral hemorrhage: insights into clinically relevant thromboembolic events from the ANNEXA-I study
by: Mateo Porres-Aguilar, et al.
Published: (2025-01-01) -
Management of factor Xa inhibitor–related traumatic non‐intracranial bleeding events with andexanet alfa or four‐factor prothrombin complex concentrate in a US multicenter observational study
by: Paul P. Dobesh, et al.
Published: (2024-12-01)